Last updated: March 12, 2026
Case Overview
Bracco Diagnostics Inc. filed suit against Maia Pharmaceuticals Inc. on December 21, 2017, in the District of New Jersey. The case involves claims of patent infringement related to nuclear imaging agents used in diagnostic procedures.
The dispute centers on U.S. Patent No. 7,868,271 (the '271 patent), which covers methods for preparing technetium-99m labeled compounds used in medical imaging. Bracco alleges that Maia's product, which involves a similar technetium-99m labeling process, infringes the patent rights.
Procedural Posture
- Complaint Filed: December 21, 2017
- Defendant's Initial Response: Maia filed a motion to dismiss on June 12, 2018, arguing that the patent claims are invalid due to obviousness and lack of novelty.
- Summary Judgment Motions: Both parties filed briefing on infringement and validity issues.
- Trial: Scheduled for October 2020 but later delayed to allow for settlement discussions.
- Current Status (as of 2023): The case remains active with ongoing settlement negotiations and discovery disputes.
Patent and Legal Claims
- Patent: U.S. Patent 7,868,271, entitled "Preparation of technetium-99m labeled compounds."
- Claims: Focus on specific chemical preparation and labeling processes that improve efficiency and purity.
- Allegations: Maia's process infringes claims by utilizing similar chemical steps without license.
Key Litigation Issues
Patent Validity
Maia challenges the '271 patent on grounds of obviousness under 35 U.S.C. § 103, asserting that prior art references, including earlier patents and scientific publications, render the claims obvious. Bracco counters that the patent involves unexpected results and inventive steps not disclosed in prior art.
Infringement
Bracco argues Maia's process and products directly infringe on multiple claims of the '271 patent. Maia disputes infringement, claiming its process differs materially and does not infringe the specific steps or chemical compositions claimed.
Damages and Injunctive Relief
Bracco seeks monetary damages for infringement and an injunction against Maia’s sales of infringing products. The specific damages amount remains contested, with Maia denying liability.
Expert Testimony
Expert reports from both sides address issues of patent scope, prior art references, and the technical differences in the processes. Disputes over the interpretation of scientific data complicate the case.
Settlement and Disputes
Limited progress has been made toward settlement due to ongoing legal and technical challenges. Discovery disputes over certain proprietary data and depositions have extended pre-trial preparations.
Recent Developments
- 2019: Court granted Maia’s motion to stay certain proceedings pending reexamination of the patent by the USPTO.
- 2020: Reexamination concluded with the USPTO maintaining the patent claims.
- 2021-2022: Both parties engaged in settlement negotiations; no final resolution yet.
Strategic Implications
The case underscores risks associated with patent challenges based on obviousness defenses, especially in complex chemical and pharmaceutical technologies. Enforcement efforts remain active despite patent reexaminations and procedural delays.
Pharmaceutical and medical diagnostic companies frequently face patent litigation when introducing novel imaging agents, with patent scope and prior art validity heavily contested.
Key Takeaways
- The case revolves around patent infringement and validity in the nuclear imaging field.
- Maia challenges the patent based on obviousness, but the USPTO reexamined and upheld the patent claims.
- The case highlights the importance of patent drafting and prior art analysis in biotech patent strategies.
- Settlement negotiations are ongoing, but litigation risks persist.
- Similar cases could influence licensing and product development in the nuclear medicine sector.
FAQs
Q1: What are the main legal grounds Maia uses to challenge the patent?
A1: Maia primarily argues that the patent claims are invalid due to obviousness under 35 U.S.C. § 103 based on prior art references.
Q2: Has the USPTO reexamined and validated the patent claims?
A2: Yes, following reexamination initiated in 2019, the USPTO upheld the validity of the patent claims in 2020.
Q3: What damages does Bracco seek?
A3: Bracco seeks monetary damages for patent infringement and an injunction to prevent Maia from selling infringing products.
Q4: How does the case affect the development of imaging agents?
A4: The case emphasizes patent protection’s significance in encouraging innovation and risk management in biotech product development.
Q5: What trends does this case illustrate about patent litigation in biotech?
A5: It illustrates frequent patent reexaminations, challenge strategies based on prior art, and continued enforcement despite procedural delays.
References
- U.S. Patent No. 7,868,271. (2011). Preparation of technetium-99m labeled compounds.
- Court docket for Bracco Diagnostics Inc. v. Maia Pharmaceuticals Inc., 3:17-cv-13151-PGS-TJB (District of New Jersey, 2017).
